Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Jules I. Schwartz"'
Autor:
Anish Mehta, Jules I. Schwartz, William Taggart, Howard E. Greenberg, Wesley Tanaka, Keith Gottesdiener, Bret J. Musser
Publikováno v:
Clinical Pharmacology in Drug Development. 4:337-345
This double-blind, randomized crossover study assessed the effect of acetaminophen (1000 mg every 8 hours) versus indomethacin (50 mg every 8 hours) versus placebo on cyclooxygenase enzymes (COX-1 and COX-2). Urinary excretion of 2,3-dinor-6-keto-PGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c58b3f9593566cddcc35de2d14345d5
https://doi.org/10.1002/cpdd.194
https://doi.org/10.1002/cpdd.194
Autor:
Lisa Ratcliffe, Amy O. Johnson-Levonas, Wen-Lin Luo, Jules I. Schwartz, Jan de Hoon, Victor Dishy, Eseng Lai, Julie Mabalot Luk, John A. Wagner, Anne Van Hecken, Waldemar Radziszewski, Walter K. Kraft, Aimee Dallob, Inge De Lepeleire
Publikováno v:
Platelets. 22:495-503
Laropiprant (LRPT) is being developed in combination with Merck's extended-release niacin (ERN) formulation for the treatment of dyslipidemia. LRPT, an antagonist of the prostaglandin PGD2 receptor DP1, reduces flushing symptoms associated with ERN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94880ac79925cac8bcf858465a5ad9ff
https://doi.org/10.3109/09537104.2011.565433
https://doi.org/10.3109/09537104.2011.565433
Autor:
Jules I. Schwartz, John A. Wagner, Larissa Wenning, Rajesh Desai, Patricia Jumes, Wen-Lin Luo, Ying-Hong Wang, Eseng Lai
Publikováno v:
Cardiovascular Therapeutics. 29:140-145
Laropiprant is a selective antagonist of the prostaglandin D2 receptor subtype 1, and is primarily eliminated via glucuronidation with a minor contribution from oxidative metabolism via CYP3A. The effects of multiple oral doses of clarithromycin on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ca62e7a26f282bcaace854966e24823
https://doi.org/10.1111/j.1755-5922.2009.00129.x
https://doi.org/10.1111/j.1755-5922.2009.00129.x
Autor:
Keith Gottesdiener, Jutta L. Miller, Thomas Marbury, Nancy G. B. Agrawal, Paul F. Cavanaugh, David Hoelscher, Jules I. Schwartz, Kenneth Bachmann, Peggy H. Wong
Publikováno v:
The Journal of Clinical Pharmacology. 49:1202-1209
The authors designed 2 randomized controlled studies to examine the effects of etoricoxib 60 to 120 mg daily on methotrexate pharmacokinetics in 50 rheumatoid arthritis (RA) patients on stable doses of methotrexate (7.5-20 mg). Patients received oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65754b447f1e89c887f738e82b264bf6
https://doi.org/10.1177/0091270009338939
https://doi.org/10.1177/0091270009338939
Autor:
Kenneth C. Lasseter, Eseng Lai, Fang Liu, John A. Wagner, Adrianna Gipson, Mark Stroh, Amy O. Johnson-Levonas, Jules I. Schwartz
Publikováno v:
American Journal of Therapeutics. 16:215-223
Laropiprant (LRPT), a prostaglandin D2 receptor 1 antagonist shown to reduce niacin-induced flushing symptoms, is being developed in combination with niacin for the treatment of dyslipidemia. This study assessed the pharmacokinetics/pharmacodynamics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98706bf68a8e15707cd21adc9f330678
https://doi.org/10.1097/mjt.0b013e31818f9c68
https://doi.org/10.1097/mjt.0b013e31818f9c68
Autor:
Susie Li, Stephanie Dunbar, Amy O. Johnson-Levonas, John A. Wagner, Kim Rosko, Jinyu Yuan, Jules I. Schwartz, Deborah L. Miller, Kenneth C. Lasseter
Publikováno v:
The Journal of Clinical Pharmacology. 49:72-79
Taranabant, an orally active, potent, and highly selective CB-1 receptor inverse agonist, is being developed for the treatment of obesity. This randomized, placebo-controlled, multiple-dose, crossover study evaluated the effect of taranabant on the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f545f15c9334d3e9e8bc18a5d1f0ad94
https://doi.org/10.1177/0091270008325930
https://doi.org/10.1177/0091270008325930
Autor:
Deborah Hilliard, Jules I. Schwartz, Derek L Chappell, Karen Snyder, Omar F Laterza, Patrick Larson, Jutta Miller, Mary Flynn, John A. Wagner, Jane Royalty, Aimee Dallob, Paul F. Cavanaugh
Publikováno v:
The Journal of Clinical Pharmacology. 48:745-754
We determined cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibition in healthy middle-aged subjects (41-65 years) randomly assigned to four 7-day treatment sequences of etoricoxib 90 mg every day, celecoxib 200 mg twice a day, diclofenac 75 mg twice a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cb6ad034ecc121a79249ee904f1db4
https://doi.org/10.1177/0091270008317590
https://doi.org/10.1177/0091270008317590
Autor:
Kenneth C. Lasseter, David Hreniuk, Barry J. Gertz, Deborah Hilliard, Chau Thach, Jutta Miller, Jules I. Schwartz, Keith Gottesdiener, Karen Snyder
Publikováno v:
The Journal of Clinical Pharmacology. 47:1521-1531
This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily. Male and female subjects 60 to 81 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c84996274e4f98ffcce89ecdc932784
https://doi.org/10.1177/0091270007307878
https://doi.org/10.1177/0091270007307878
Autor:
Peggy H. Wong, Catherine Z. Matthews, Josee Cote, Marshall Sack, Nancy G. B. Agrawal, Eric Woolf, Arturo G. Porras, Richard Robson, Leslie A. Geer, Suzanne K. Swan, W. F. Kline, Ralph S. Mazenko, Kevin J. Petty, Harry Alcorn, Keith Gottesdiener, Meehung Cho, Thomas Marbury, Jack W. Moncrief, Jules I. Schwartz
Publikováno v:
The Journal of Clinical Pharmacology. 44:48-58
The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7173647acce972895a25e7da4563bae1
https://doi.org/10.1177/0091270003260338
https://doi.org/10.1177/0091270003260338
Autor:
Sheila A Merschman, Barry J. Gertz, Kala-Jyoti Viswanathan-Aiyer, Nancy G. B. Agrawal, Kenneth C. Lasseter, Arturo G. Porras, Patrick Larson, Jules I. Schwartz, Ralph S Mazenko
Publikováno v:
Clinical Drug Investigation. 23:503-509
Objective: Rofecoxib suspension is a formulation developed to increase the convenience of rofecoxib therapy for patients who have difficulty swallowing tablets. This open-label, two-part study compared the single-dose pharmacokinetics of rofecoxib ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a466db050fafae19236cce54fb8af15a
https://doi.org/10.2165/00044011-200323080-00002
https://doi.org/10.2165/00044011-200323080-00002